0000000000408200

AUTHOR

Nikolaos Patsinakidis

showing 3 related works from this author

Resistance to water and abrasion of a broad-spectrum sunscreen: a prospective, open-label study.

2015

1303 BiochemistryFrictionAbrasion (mechanical)Ultraviolet RaysDrug Evaluation PreclinicalSunburn610 Medicine & healthSunscreening AgentsDermatologyAdministration Cutaneous030226 pharmacology & pharmacyBiochemistry2708 Dermatology03 medical and health sciencesBroad spectrum0404 agricultural biotechnology0302 clinical medicineOpen label study1312 Molecular BiologymedicineHumansProspective StudiesSunburnComposite materialMolecular BiologySkin damageSkinWater resistanceChemistry10177 Dermatology ClinicWater04 agricultural and veterinary sciencesmedicine.disease040401 food scienceLiposomesHydrophobic and Hydrophilic InteractionsSunscreening AgentsExperimental dermatology
researchProduct

Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCL…

2012

In this prospective, cross-sectional, multicenter study, we assessed clinical and laboratory characteristics from patients with cutaneous lupus erythematosus (CLE) using the Core Set Questionnaire of the European Society of Cutaneous Lupus Erythematosus (EUSCLE). 1002 (768 females, 234 males) patients with different subtypes of CLE, such as acute CLE (ACLE, 304 patients), subacute CLE (SCLE, 236 patients), chronic CLE (CCLE, 397 patients), and intermittent CLE (ICLE, 65 patients), from 13 European countries were collected and statistically analyzed by an SPSS database. The main outcome measures included gender, age at onset of disease, LE-specific and LE-nonspecific skin lesions, photosensi…

AdultMalemedicine.medical_specialtyPathologyDatabases FactualAnti-nuclear antibodyCross-sectional studyImmunologyDiseaseDiagnosis Differential030207 dermatology & venereal diseases03 medical and health sciencesSex Factors0302 clinical medicineSurveys and QuestionnairesInternal medicineLupus Erythematosus CutaneousmedicineHumansImmunology and AllergyProspective StudiesAge of OnsetGeography MedicalProspective cohort studyAgedSkin030203 arthritis & rheumatologyAutoimmune diseaseLupus erythematosusbusiness.industryfungiAge FactorsMiddle Agedmedicine.diseaseDermatologyRheumatology3. Good healthEuropeCross-Sectional StudiesFemaleAge of onsetbusinessAutoimmunity Reviews
researchProduct

Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study.

2016

Objective The aim of the study was to assess the efficacy and safety of fumaric acid esters (FAEs) in patients with cutaneous lupus erythematosus (CLE). Methods In this 24-week, prospective, open-label, phase II pilot study, 11 patients with CLE, refractory to topical corticosteroids, were included. The primary endpoint of the study was the evaluation of the efficacy of FAEs after 24 weeks of treatment as assessed by the Revised Cutaneous Lupus Disease Area and Severity Index (RCLASI). Results Compared to baseline, significant improvement in the mean total RCLASI activity score and the mean RCLASI activity score for skin lesions was observed in week 12 ( p = 0.002, p = 0.002, respectively) …

AdultMaleFumaric acidmedicine.medical_specialtyColicPilot ProjectsSeverity of Illness IndexDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRheumatologyFumaratesLupus Erythematosus CutaneousMedicineHumansIn patientProspective Studies030203 arthritis & rheumatologybusiness.industryHeadacheMiddle AgedDermatologyAlternative treatmentClinical trialTreatment OutcomeFumaric Acid EsterschemistryCutaneous Lupus ErythematosusFemaleOpen labelbusinessLupus
researchProduct